Results 231 to 240 of about 44,966 (284)

Recent Progress on Enzyme Immobilization: Materials, Strategies, and Applications

Food Bioengineering, EarlyView.
Enzyme immobilization technology has undergone substantial evolution driven by advances in materials science. This review systematically examines the recent advances in enzyme immobilization since 2024, with a focused analysis of five major categories of enzyme carriers including covalent organic framework, metal‐organic frameworks, polymers, carbon ...
Shuran Wang, Ruoke Li, Yixuan Xie, Hanya Zhang, Xiaoyu Huang, Siwei Chen, Weixin Xu, Yueling Liu   +7 more
wiley   +1 more source

Defining a Quantitative Threshold for Adaptive Re-planning using a Percentile-based Scoring System. [PDF]

Int J Part Ther
Leone AO, Peterson CB, Lee A, Garden AS, Gunn GB, Mayo LL, Moreno AC, Frank SJ, Fuller CD, Reddy JP, Hoffman K, Vazquez I, Yang M, Niedzielski JS, Court LE, Whitaker TJ.   +15 more
europepmc   +1 more source

DOSE-DRIVEN CONTOUR-GUIDANCE TOOL FOR ONLINE ADAPTIVE PROTON THERAPY

International Journal of Particle Therapy
Lisa Fankhauser, Andreas Smolders, Antony John Lomax, Francesca Albertini   +3 more
openaire   +1 more source

In Vitro Characterization of Technological and Health‐Promoting Properties of Enterocin Producing Lactic Acid Bacteria From Camel Milk and Its Suitability as a Dairy Starter

Food Chemistry International, EarlyView.
Enterocin‐producing Enterococcus faecium RSCUDR7 from camel milk exhibited strong probiotic and antimicrobial properties, along with stability in skim milk. Its suitability as a safe and effective dairy starter highlights its potential for developing functional probiotic dairy products.
Rahul Singhal, Kamalesh Kumar Meena, Manvik Joshi, Lokesh Gupta, Sunil Meena   +4 more
wiley   +1 more source

Commissioning and clinical implementation of Monaco treatment planning system on a compact pencil beam scanning proton therapy system. [PDF]

J Appl Clin Med Phys
Xu X, Cong X, Liang J, Qin A, Chen S, Li X, Zheng W, Liu P, Dalfsen R, Dolan J, Soukup M, Stevens C, Deraniyagala R, Ding X.   +13 more
europepmc   +1 more source

Intraoperative Indocyanine Green Fluorescence Enables Primary Tumor Localization and Treatment De‐Escalation in SCCUP: A Case Report

Head &Neck, EarlyView.
ABSTRACT Background Unknown primary cancer in the head and neck presents a difficult surgical treatment dilemma. Patients with squamous cell carcinoma of unknown primary (SCCUP) typically present with an enlarging neck mass found on biopsy but with no indication of primary site on diagnostic exams such as flexible laryngoscopy, CT, MRI, and/or PET/CT ...
Nikhil Bellamkonda, Nitish Khurana, Eric Babajanian, Hamidreza Ghandehari, Jeremiah A. Alt, Richard B. Cannon   +5 more
wiley   +1 more source

From Photons to Protons in Gastrointestinal Cancers: A Journey of Transition, Awe, Challenge, and Renewed Hope. [PDF]

Int J Part Ther
Abhishek A.
europepmc   +1 more source

Radiobiological and Clinical Advantages of Proton Therapy in Modern Cancer Treatment. [PDF]

Cancers (Basel)
Kalospyros SA, Gkikoudi A, Koutsostathis A, Adamopoulou A, Vasilopoulos SN, Rangos V, Stylianou-Markidou E, Pantalos I, Koumenis C, Georgakilas AG.   +9 more
europepmc   +1 more source

Polygenic risk score and prostate specific antigen predict death from prostate cancer in men with intermediate aggressive cancer

International Journal of Cancer, EarlyView.
What's New? Using 21 SNPs, two novel PRS were constructed and used to develop two new machine‐learning classifiers, one for the detection of prostate cancer and the other for the prediction of its aggressiveness and subsequent mortality. The classifier for disease detection is built using the PRS as the sole feature, whereas the one for disease ...
Leandro Rodrigues Santiago, Efthymios Ladoukakis, Dorota Scibior‐Bentkowska, Belinda Nedjai   +3 more
wiley   +1 more source

Combination of Lenvatinib and Antibiotics: A Potential Approach to Enhance Sensitivity in Differentiated Thyroid Cancer

International Journal of Cancer, EarlyView.
Although lenvatinib is the current first‐line therapy for radioiodine‐refractory differentiated thyroid carcinoma, its use is limited by severe side effects and reduced sensitivity. Here, the authors assessed the potential of sensitizing differentiated thyroid carcinoma tumor cells with limited lenvatinib responsiveness through the administration of ...
Celina Ablinger, Petra Huber‐Cantonati, Daniela D. Weber, Sarah Pichler, Georg Schischkow, Marta Garcia‐Miralles, Christian Pirich, Gundula Rendl, Teresa Kiener, Thomas Felder, Martin Geroldinger, Robert Terkola, Barbara Kofler, Johanna Pachmayr   +13 more
wiley   +1 more source